表紙
市場調查報告書

新型冠狀病毒 (COVID-19):開發中的預防疫苗、治療藥、診斷藥

Novel Coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development

出版商 ROOTS ANALYSIS 商品編碼 926043
出版日期 內容資訊 英文 122 Pages
商品交期: 最快1-2個工作天內
價格
新型冠狀病毒 (COVID-19):開發中的預防疫苗、治療藥、診斷藥 Novel Coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development
出版日期: 2020年02月28日內容資訊: 英文 122 Pages
簡介

目前,針對新型冠狀病毒 (COVID-19) 的預防、治療之疫苗和醫藥品開發,製藥及生物科技企業、政府機構、研究機構正進行近30件研究計畫,並實行超過40件診斷測試的開發。此外,由於對於醫療負擔不斷增加,也吸引了大規模資金投入以推動醫藥品開發,包含Bill&Melinda Gates Foundation所提供的1億美元、英國政府出資2,600萬美元協助疫苗開發等。雖然開發主體各種規模的企業交雜,但大型企業、超大型企業佔了整體利害相關者的60%;而30%以上的開發者為學術機構也是一大特徵。除了DNA及RNA疫苗之外,企業也聚焦於單株抗體和小分子抑制劑。多數企業正進行生物製劑候補的評估,而部分企業也致力於重新利用已核准的小分子藥物候補於COVID-19。

本報告研究新型冠狀病毒 (COVID-19) 的預防、治療、診斷之疫苗和藥劑候補、診斷測試開發趨勢,彙整主要開發主體,候補藥的開發階段、分子區分、區域等的分佈,以及候補藥作用機制和投藥路徑、臨床試驗設計、社群媒體平台Twitter分析、各種補助款相關分析、主要相關業者簡介等情報。

第1章 前言

第2章 摘要整理

第3章 COVID-19:市場環境

  • 本章概要
  • COVID-19:診斷藥開發者名單
    • 按設立年份
    • 按企業規模
    • 按區域
  • COVID-19:治療藥開發者名單
    • 按設立年份
    • 按企業規模
    • 按區域
  • 按區域摘要

第4章 籌資與投資分析

  • 本章概要
  • COVID-19:籌資案例名單
    • 按主要投資家

第5章 研究資金補助分析

  • 本章概要
  • 研究範圍和方法
  • COVID-19:研究資金補助分析
    • 按補助年份
    • 按補助額
    • 按管轄機構
    • 按補助期間
    • 按補助估購和補助期間
    • 按補助機制
    • 按補助款申請類型
    • 熱門的NIH部門
    • 按收受組織類型分析
    • 主要保健機構
    • 按補助機制
    • 主要計畫人員
    • 主要意見領袖
    • 收受者區域分佈

第6章 臨床試驗分析

  • 本章概要
  • 研究範圍和方法
  • COVID-19:臨床試驗名單
    • 按試驗狀態分析
    • 按試驗階段
    • 按試驗設計
    • 按贊助/合作類型
    • 區域分析:臨床試驗數
    • 區域分析:被試驗者數

第7章 社群媒體分析

  • 本章概要
  • 研究範圍和方法
  • COVID-19:Twitter趨勢
    • 每週累積活動:按推文量
    • 推文量近期趨勢
    • 趨勢字/文句
    • Twitter最多的貢獻者
  • 結論

第8章 結論

  • 本章概要
  • 重要要點

第9章 附錄1:匯總數據

第10章 附錄2:企業和組織名單

目錄

Example Insights:

  • More than 30 drug developers presently claim to be developing drugs for the treatment of COVID-19 infections. The market landscape is fragmented, featuring a mix of companies of all sizes; however, large and very-large companies represent 60% of the overall number of industry stakeholders. It is worth highlighting that more than 30% of the developers involved in the development of therapeutic agents are academic institutes.
  • Besides DNA and RNA vaccines, companies are focused on monoclonal antibodies, as well as small molecule inhibitors. Majority of the companies are evaluating biologic drug candidates, while some of the players are working on repurposing previously approved small molecule drug candidates for the treatment of patients infected with COVID-19.
  • Close to 25 clinical trials have already been registered enrolling over 2000 patients, till date. More than 80% of the patients enrolled in the clinical trials are based in China. Some of the top clinical trial sponsors include (illustrative list) Huazhong University of Science and Technology, French National Institute of Health and Medical Research, Beijing 302 Hospital, Shanghai Public Health Clinical Center, Peking Union Medical College Hospital, Capital Medical University, and Chinese Academy of Medical Sciences.
  • Over 40 diagnostic tests are under development for timely detection of the infection. More than 50% of the diagnostic tests are being developed by the companies based in Asia Pacific, with over 85% of these based in China and South Korea. Of the disclosed diagnostic tests, close to 60% are based on RT-PCR.
  • Evaluation of historical grant data has revealed over 140 KOLs related to coronavirus. Since 1995, over 2000 NIH funded grants have been awarded for research related to coronavirus with cumulative grant amount totalling over USD 2 billion, provided through various funding mechanisms.

Overview:

New coronavirus (COVID-19) is a previously unidentified strain of coronavirus, that first emerged in the Chinese city of Wuhan in December 2019. The virus belongs to the same family as the virus that causes severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). On 30th January 2020, the World Health Organization (WHO) declared the coronavirus outbreak as a global health emergency. In fact, the virus is estimated to have infected more than 45,000 individuals, around the globe (estimates till the second week of February 2020). In order to deal with this outbreak and prevent the spread of virus to new geographies, countries are adopting various precautions. The WHO has recently released the Strategic Preparedness and Response Plan (SPRP) that lays out activities and resources needed by international health organizations globally, including WHO, to implement priority public health measures in support of countries to prepare and respond to COVID-19 for a period between February to April 2020.

Close to 30 pharmaceutical / biotechnology companies, government agencies, and research institutes have disclosed research programs focused on developing vaccines / drugs to prevent or treat COVID-19 infections. In addition, more than 40 diagnostic tests are currently being developed for effective diagnosis of patients. The rising healthcare burden of the disease has also attracted significant funding to fuel drug development efforts in this space; recent funding initiatives include USD 100 million funding by Bill & Melinda Gates Foundation, and USD 26 million vaccine development fund by the UK government.

Scope of the Report:

The “Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development” report features an extensive study of the vaccine / drug candidates and diagnostic tests being investigated for COVID-19 infection prevention, treatment and diagnosis. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of vaccines and drugs being developed for the prevention and treatment of COVID-19 infection, providing information on the developer(s), phase of development (clinical, preclinical, discovery) of product candidates, type of molecule (vaccines, antibodies, small molecules, others), mechanism of action, route of administration, funding agency, and key collaborators.
  • A detailed clinical trial analysis of completed, ongoing and planned studies of candidates being evaluated for the treatment of COVID-19, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration date, enrolled patient population and regional distribution of trials, type of drug being evaluated, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, and clinical endpoints.
  • A detailed assessment of the diagnostic tests being developed for the diagnosis of COVID-19 infection, providing information on test developer(s), development geography, technology being used in the test, time to result, and, test sample type.
  • An analysis depicting the prevalent and emerging trends related to this domain as represented on the social media platform, Twitter. In addition to providing information on day-on-day trends related to the volume of tweets, the analysis highlights the most frequently talked about areas, active players, and influential authors.
  • An in-depth analysis of more than 2,100 grants that have been awarded to research institutes engaged in projects related to coronavirus, highlighting various important parameters associated with grants, such as year of award, support period, amount awarded, funding institute, administration institute center, funding institute center, funding mechanism, spending categorization, grant type, responsible study section, focus area, type of recipient organization and prominent program officers. It also features a detailed 2X2 plot comparing the key opinion leaders based on parameters, such as amount awarded and number of awarded grants.
  • An analysis of the investments made across different companies/ academic institutes driving development efforts in this space. The analysis specifically highlights the key investors involved in this space.
  • Elaborate profiles of the key players involved in vaccine / drug and diagnostic development. Each profile features a brief overview of the company, information on its development programs, details related to funding, and collaborations related to COVID-19.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. COVID-19: MARKET LANDSCAPE

  • 3.1. Chapter Overview
  • 3.2. COVID-19: List of Diagnostics Developers
    • 3.2.1. Analysis by Year of Establishment
    • 3.2.2. Analysis by Company Size
    • 3.2.3. Analysis by Regions
  • 3.3. COVID-19: List of Therapeutics Developers
    • 3.3.3. Analysis by Year of Establishment
    • 3.3.2. Analysis by Company Size
    • 3.3.3. Analysis by Regions
  • 3.4. Regional Summary

4. FUNDING AND INVESTMENT ANALYSIS

  • 4.1. Chapter Overview
  • 4.2. COVID-19: List of Funding Instances
    • 4.2.1. Analysis by Top Investors

5. ACADEMIC GRANT ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Scope and Methodology
  • 5.3. COVID-19: Academic Grant Analysis
    • 5.3.1. Analysis by Year of Award
    • 5.3.2. Analysis by Amount Awarded
    • 5.3.3. Analysis by Administering Institute Center
    • 5.3.4. Analysis by Support Period
    • 5.3.5. Analysis by Funding Institute Center and Support Period
    • 5.3.6. Analysis by Funding Mechanism
    • 5.3.7. Analysis by Type of Grant Application
    • 5.3.8. Popular NIH Departments
    • 5.3.9. Analysis by Type of Recipient Organization
    • 5.3.10. Popular Recipient Organizations
    • 5.3.11. Analysis By Grant Mechanism
    • 5.3.12. Prominent Program Officers
    • 5.3.13. Key Opinion Leaders
    • 5.3.14. Regional Distribution of Recipient Organization

6. CLINICAL TRIAL ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Scope and Methodology
  • 6.3. COVID-19: List of Clinical Trials
    • 6.3.1. Analysis by Trial Status
    • 6.3.2. Analysis by Trial Phase
    • 6.3.3. Analysis by Study Design
    • 6.3.4. Analysis by Type of Sponsor / Collaborator
    • 6.3.5. Geographical Analysis by Number of Clinical Trials
    • 6.3.6. Geographical Analysis by Enrolled Patient Population

7. SOCIAL MEDIA ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. COVID-19: Trends on Twitter
    • 7.3.1. Cumulative Week-wise Activity by Volume of Tweets
    • 7.3.2. Recent Trends in Volume of Tweets
    • 7.3.3. Trending Words / Phrases on Twitter
    • 7.3.4. Most Prolific Contributors on Twitter
  • 7.4. Concluding Remarks

8. CONCLUDING REMARKS

  • 8.1. Chapter Overview
  • 8.2. Key Takeaways

9. APPENDIX 1: TABULATED DATA

10. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

  • Figure 3.1: COVID-19 Diagnostics Developers: Distribution by Year of Establishment
  • Figure 3.2: COVID-19 Diagnostics Developers: Distribution by Company Type
  • Figure 3.3: COVID-19 Diagnostics Developers: Distribution by Regions
  • Figure 3.4: COVID-19 Therapeutics Developers: Distribution by Year of Establishment
  • Figure 3.5: COVID-19 Therapeutics Developers: Distribution by Company Type
  • Figure 3.6: COVID-19 Therapeutics Developers: Distribution by Regions
  • Figure 3.7: COVID-19 Diagnostics and Therapeutics Developers : Regional Distribution
  • Figure 4.1: COVID-19: Cumulative Number of Funding Instances
  • Figure 4.2: COVID-19: Distribution of Amount by Purpose of Funding (USD Million)
  • Figure 4.3: COVID-19: Top Investors
  • Figure 5.1: Grant Analysis: Cumulative Trend by Year of Projects, 1985-2020
  • Figure 5.2: Grant Analysis: Trend by Amount Awarded, 2011-2019 (USD Million)
  • Figure 5.3: Grant Analysis: Distribution by Administering Institute Center
  • Figure 5.4: Grant Analysis: Distribution by Support Period
  • Figure 5.5: Grant Analysis: Distribution by Funding Institute Center and Support Period
  • Figure 5.6: Grant Analysis: Distribution by Funding Mechanism
  • Figure 5.7: Grant Analysis: Distribution by Type of Grant Application
  • Figure 5.8: Grant Analysis: Popular NIH Departments
  • Figure 5.9: Grant Analysis: Type of Recipient Organization
  • Figure 5.10: Grant Analysis: Popular Recipient Organizations
  • Figure 5.11: Grant Analysis: Popular Funding Mechanism
  • Figure 5.12: Grant Analysis: Prominent Program Officers
  • Figure 5.13: Grant Analysis: Regional Distribution of Recipient Organization
  • Figure 6.1: Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 6.2: Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 6.3: Clinical Trial Analysis: Distribution of Enrolled Patients by Trial Phase
  • Figure 6.4: Clinical Trial Analysis: Distribution by Study Design
  • Figure 6.5: Clinical Trial Analysis: Top Sponsors
  • Figure 6.6: Clinical Trial Analysis: Geographical Distribution by Number of Trials
  • Figure 6.7: Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
  • Figure 7.1: Social Media Analysis: Cumulative Week-Wise Activity by Volume of Tweets
  • Figure 7.2: Social Media Analysis: Historical Trends on Twitter
  • Figure 7.4: Social Media Analysis: Trending Words / Phrases on Twitter
  • Figure 7.5: Social Media Analysis: Most Prolific Contributors on Twitter

LIST OF TABLES

  • Table 4.1: COVID-19: List of Diagnostics Developer
  • Table 4.2: COVID-19: List of Therapeutics Developer
  • Table 5.1: COVID-19: Funding and Investments
  • Table 6.1: COVID-19: List of Clinical Trials
  • Table 6.2: COVID-19: List of Sponsors
  • Table 10.1: COVID-19 Diagnostics Developers: Distribution by Year of Establishment
  • Table 10.2: COVID-19 Diagnostics Developers: Distribution by Company Size
  • Table 10.3: COVID-19 Diagnostics Developers: Distribution by Regions
  • Table 10.4: COVID-19 Therapeutics Developers: Distribution by Year of Establishment
  • Table 10.5: COVID-19 Therapeutics Developers: Distribution by Company Size
  • Table 10.6: COVID-19 Therapeutics Developers: Distribution by Regions
  • Table 10.7: COVID-19: Cumulative Number of Funding Instances
  • Table 10.8: COVID-19: Distribution of Amount by Purpose of Funding (USD Million)
  • Table 10.9: COVID-19: Top Investors
  • Table 10.10: Grant Analysis: Cumulative Trend by Year of Projects, 1985-2020
  • Table 10.11: Grant Analysis: Trend by Amount Awarded, 2011-2019 (USD Million)
  • Table 10.12: Grant Analysis: Distribution by Administering Institute Center
  • Table 10.13: Grant Analysis: Distribution by Support Period
  • Table 10.14: Grant Analysis: Distribution by Funding Institute Center and Support Period
  • Table 10.15: Grant Analysis: Distribution by Funding Mechanism
  • Table 10.16: Grant Analysis: Distribution by Type of Grant Application
  • Table 10.17: Grant Analysis: Popular NIH Departments
  • Table 10.18: Grant Analysis: Type of Recipient Organization
  • Table 10.19: Grant Analysis: Popular Recipient Organizations
  • Table 10.20: Grant Analysis: Popular Funding Mechanism
  • Table 10.21: Grant Analysis: Prominent Program Officers
  • Table 10.22: Grant Analysis: Regional Distribution of Recipient Organization
  • Table 10.23: Clinical Trial Analysis: Distribution by Trial Phase
  • Table 10.24: Clinical Trial Analysis: Distribution by Trial Phase
  • Table 10.25: Clinical Trial Analysis: Distribution of Enrolled Patients by Trial Phase
  • Table 10.26: Clinical Trial Analysis: Distribution by Study Design
  • Table 10.27: Clinical Trial Analysis: Top Sponsors
  • Table 10.28: Clinical Trial Analysis: Geographical Distribution by Number of Trials
  • Table 10.29: Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
  • Table 10.30: Social Media Analysis: Cumulative Week-Wise Activity by Volume of Tweets
  • Table 10.31: Social Media Analysis: Most Prolific Contributors on Twitter